13 Jun Anocca
Anocca is leveraging its innovative platform approach to develop transformative T Cell Receptor (TCR) engineered-T cell (TCR-T) immunotherapies to treat solid tumours. The company has validated and deployed a proprietary precision biology platform that enables assumption-free discovery of targets and fully characterised TCRs at an industrial scale with unmatched speed and precision. Anocca has a fully integrated R&D infrastructure, underpinned by tailor-made advanced software solutions, and complemented by an in-house clinical manufacturing and process development facility. The platform has generated a broad preclinical pipeline of asset libraries with blockbuster potential and expects to progress several TCR-T therapies to the clinic in the near term. Founded in 2014, Anocca is led by an experienced management team that has raised over USD 100 million in funding from a small group of private investors. Anocca’s team of over 80 employees operate from its site in Södertälje, Sweden. www.anocca.com
